findmyKOL
Clinical trialNCT00210353CompletedPhase 3Interventional

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

SponsorInternational Extranodal Lymphoma Study Group (IELSG)Enrollment454Lymphoma, Mucosa-Associated Lymphoid Tissue
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and determine whether the addition of Rituximab to Chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with Chlorambucil alone. In April 2006, a third arm of treatment was added to compare the antitumor activity and safety of rituximab alone vs chlorambucil alone
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Catherine Thieblemont, MD

    Centre Hospitalier Lyon Sud, Hematology. Lyon

    Study Chair
    clinicaltrials.gov ↗
  • Emanuele Zucca, MD

    International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland. Bellinzona

    Study Chair
    clinicaltrials.gov ↗
  • Emilio Montserrat, MD

    Clinic Hospital Universitari, Hematology. Barcelona

    Study Chair
    clinicaltrials.gov ↗
  • Giovanni Martinelli, MD

    Hemato-oncology. European Oncology Institute. Milan

    Study Chair
    clinicaltrials.gov ↗
  • Maurizio Martelli, MD

    Hematology. Università La Sapienza. Roma

    Study Chair
    clinicaltrials.gov ↗
  • Peter Johnson, MD

    Oncology Unit. Southampton General Hospital. Southampton

    Study Chair
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

75 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Acza Campus Stuivenberg

    Antwerp, Belgium

  • Az Stjan

    Bruges, Belgium

  • St Luc

    Brussels, Belgium

  • Ulb Hopital Erasme

    Brussels, Belgium

  • Chndrf

    Charleroi, Belgium

  • Hospital St Joseph

    Gilly, Belgium

  • Ucl de Mont Godinne

    Yvoir, Belgium

France
  • Centre Hospitalier de Blois

    Blois, France

  • Hopital Avicenne

    Bobigny, France

  • Chu

    Dijon, France

  • Centre Hospitalier

    Lens, France

  • Chru Lille

    Lille, France

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Centre Leon Berard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • Hopital Arnold Villeneuve

    Monpellier, France

  • Chu

    Nancy, France

  • Chu Hotel Dieu

    Nantes, France

  • Centre R. Gauducheau

    Nantes-St. Herblain, France

  • Hopital Henri-Mondor

    Paris, France

  • Hopital St Louis

    Paris, France

  • Necker

    Paris, France

  • Centre Henri Becquerel

    Rouen, France

Italy
  • Spedali Civili

    Brescia, Italy

  • Azienda Ulss 15 Alta Padovana

    Cittadella, Italy

  • Ist

    Genova, Italy

  • Humanitas

    Milan, Italy

  • Ieo

    Milan, Italy

  • Int

    Milan, Italy

  • San Raffaele Hospital

    Milan, Italy

  • Policlinico

    Modena, Italy

  • Ospedale Civile

    Piacenza, Italy

  • A.O. Bianchi-Melacrino-Morelli, Divisione Di Ematologia

    Reggio Calabria, Italy

  • Arcispedale S. Maria Nuova

    Reggio Emilia, Italy

  • S. Eugenio

    Rome, Italy

  • Università Cattolica Sacro Cuore

    Rome, Italy

  • Università la Sapienza

    Rome, Italy

  • Sassuolo Gisl

    Sassuolo, Italy

  • Aou Senese

    Siena, Italy

  • A.O.U. San Giovanni Battista-Molinette, S.C. Ematologia 2

    Torino, Italy

35 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Chlorambucil →Rituximab →Rituximab+chlorambucil
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2003
Primary completion
30 Apr 2015
Completion
17 Feb 2016
Last update posted
6 Jun 2019
Registered enrollment
454
Registry id
NCT00210353
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.